The Beauty Health Company (NASDAQ:SKIN) Given Average Rating of “Reduce” by Brokerages

Shares of The Beauty Health Company (NASDAQ:SKIN) have been given an average recommendation of “Reduce” by the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $2.46.

A number of equities analysts have recently commented on SKIN shares. Stifel Nicolaus reduced their price objective on shares of Beauty Health from $4.00 to $2.00 and set a “hold” rating for the company in a report on Friday, July 26th. Piper Sandler reaffirmed an “underweight” rating and set a $1.00 price objective (down from $1.50) on shares of Beauty Health in a report on Friday, August 9th. Finally, Canaccord Genuity Group dropped their target price on Beauty Health from $2.00 to $1.25 and set a “hold” rating for the company in a report on Monday, August 12th.

Beauty Health Trading Down 1.8 %

Shares of SKIN opened at $1.67 on Thursday. The stock’s 50-day moving average price is $1.58 and its 200 day moving average price is $1.95. The company has a quick ratio of 5.47, a current ratio of 6.49 and a debt-to-equity ratio of 7.96. Beauty Health has a 12-month low of $0.91 and a 12-month high of $5.17. The firm has a market capitalization of $207.11 million, a price-to-earnings ratio of -2.01 and a beta of 0.90.

Beauty Health (NASDAQ:SKIN) last issued its earnings results on Thursday, August 8th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). Beauty Health had a negative net margin of 22.86% and a negative return on equity of 4.57%. The firm had revenue of $90.60 million during the quarter, compared to analyst estimates of $98.46 million. As a group, research analysts predict that Beauty Health will post -0.2 earnings per share for the current year.

Insider Activity at Beauty Health

In other Beauty Health news, Chairman Brent L. Saunders acquired 40,450 shares of Beauty Health stock in a transaction on Monday, August 12th. The shares were bought at an average price of $1.08 per share, with a total value of $43,686.00. Following the completion of the purchase, the chairman now owns 5,921,769 shares in the company, valued at $6,395,510.52. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 41.00% of the company’s stock.

Hedge Funds Weigh In On Beauty Health

A number of institutional investors have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Beauty Health in the first quarter valued at approximately $4,297,000. Cohen Capital Management Inc. increased its stake in shares of Beauty Health by 344.1% in the 3rd quarter. Cohen Capital Management Inc. now owns 572,848 shares of the company’s stock valued at $825,000 after buying an additional 443,859 shares during the period. Federated Hermes Inc. raised its position in shares of Beauty Health by 349,616.0% during the second quarter. Federated Hermes Inc. now owns 370,699 shares of the company’s stock worth $712,000 after acquiring an additional 370,593 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Beauty Health by 24.9% during the second quarter. Bank of New York Mellon Corp now owns 348,108 shares of the company’s stock valued at $668,000 after acquiring an additional 69,329 shares during the period. Finally, Bayesian Capital Management LP bought a new position in Beauty Health in the first quarter valued at about $521,000. 93.26% of the stock is owned by institutional investors.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.